ArticleBMJ open2025
Combined impact of the COVID-19 pandemic and the number of comorbidities on community antibiotic utilisation rates: a population-based retrospective cohort study using linked health administrative data in Quebec, Canada.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe community antibiotic utilisation in Quebec from 2018 to 2022 and to measure the combined impact of the COVID-19 pandemic and of the number of comorbidities on utilisation rates.
methodsData from the Quebec Integrated Chronic Disease Surveillance System were used to describe monthly (for the overall antibiotics use) and annual (for the main antibiotic classes) changes in antibiotic utilisation rates from 2018 to 2022, stratified by the number of comorbidities (0, 1, 2 and ≥3) and age group (0-17, 18-64 and ≥65 years old). Poisson regression was used to measure the impact of the pandemic and of comorbidities on antibiotic utilisation rates.
resultsThe study included an annual average of 424 792 children, 1 761 582 adults 18-64 years of age and 1 490 081 adults at least 65 years old. For each number of comorbidities within each age group, the utilisation rates of overall antibiotics decreased with the arrival of the pandemic and remained low despite the return of respiratory viruses in late summer 2021. This reduction was observed for all major antibiotic classes, except for fosfomycin/nitrofurantoin in adults. The pandemic and respiratory viruses' resurgence periods in adults (≥18 years) without comorbidities were associated with decreases of 25% (95% CI 25% to 25%) and 19% (18% to 19%) (children: 63% (62% to 63%) and 37% (36% to 38%)) in antibiotic utilisation compared with the prepandemic period. In adults with three or more comorbidities, utilisation decreased less, by 13% (12% to 14%) and 7% (6% to 8%) (children: 33% (21% to 43%) and 23% (8% to 35%)), respectively. Children with two comorbidities during the pandemic period also experienced a smaller decrease in antibiotic utilisation than children without comorbidities for the same period.
conclusionIn Quebec, antibiotic utilisation decreased during the pandemic and remained low despite the resurgence of respiratory viruses in 2021. However, this decrease was less pronounced in individuals with multiple comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.